American Association for Cancer Research
00085472can193584-sup-232352_2_supp_6256875_q9c6pd.pdf (93.4 kB)

Table S2 from ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response

Download (93.4 kB)
journal contribution
posted on 2023-03-31, 03:00 authored by Mathilde Bouchet, Alexandra Lainé, Cyril Boyault, Mathilde Proponnet-Guerault, Emmanuelle Meugnier, Lamia Bouazza, Casina W.S. Kan, Sandra Geraci, Soumaya El-Moghrabi, Hector Hernandez-Vargas, Claire Benetollo, Yuji Yoshiko, Martine Duterque-Coquillaud, Philippe Clézardin, Julien C. Marie, Edith Bonnelye

Cytokines and inflammation sign gene expression array


National Center for Scientific Research

National Institute of Health and Medical Research


La Ligue Nationale


La Ligue Nationale contre le cancer labellisation

French National Cancer Institute

Labex DEVweCAN

La Ligue Nationale contre le cancer





Bone is the most common metastatic site for breast cancer. Although the estrogen-related receptor alpha (ERRα) has been implicated in breast cancer cell dissemination to the bone from the primary tumor, its role after tumor cell anchorage in the bone microenvironment remains elusive. Here, we reveal that ERRα inhibits the progression of bone metastases of breast cancer cells by increasing the immune activity of the bone microenvironment. Overexpression of ERRα in breast cancer bone metastases induced expression of chemokines CCL17 and CCL20 and repressed production of TGFβ3. Subsequently, CD8+ T lymphocytes recruited to bone metastases escaped TGFβ signaling control and were endowed with exacerbated cytotoxic features, resulting in significant reduction in metastases. The clinical relevance of our findings in mice was confirmed in over 240 patients with breast cancer. Thus, this study reveals that ERRα regulates immune properties in the bone microenvironment that contributes to decreasing metastatic growth. This study places ERRα at the interplay between the immune response and bone metastases of breast cancer, highlighting a potential target for intervention in advanced disease.